Introduction
For newly diagnosed epileptic patients, monotherapy with an antiepileptic drug is the treatment of choice. If the first drug fails, many patients are switched to another drug in monotherapy. However, one-third of patients does not attain seizure freedom with monotherapy. 1 In order to achieve better seizure control, these patients are often given combinations of antiepileptic drugs (also called polytherapy). In a review on AED combination therapy studies in animal models and in patients, Deckers et al. identified a number of combinations that have increased effectiveness compared to their individual constituents and/or to other combinations. 2 Higher effectiveness may be attained not only through higher efficacy, but also through better tolerability. The combination of carbamazepine and valproate is one of these combinations with higher effectiveness. In China, these two drugs are relatively expensive. Phenobarbital (PB) and primidone (PRM) are drugs of choice. Primidone is a desoxyphenobarbital which has PB as its active metabolite. In animal studies, the anticonvulsant activity of PRM almost equalled that of PB as chronic treatment of kindled rats, while PRM was tolerated better. 3 Few studies have been performed that have evaluated the effects of the combination of carbamazepine and primidone. The aim of the present study is compare both efficacy and tolerability of add-on valproate and add-on primidone in carbamazepineunresponsive patients with partial epilepsy.
Methods

Patients
The trial was initiated in February 2002 and was completed in October 2004. The inclusion criteria were: age 8 years and older; diagnosis of partial epilepsy, based on an accurate history and adequate neurophysiologic data; well-defined types of seizures according to the International Classification of Epileptic Seizures 4 ; patients not becoming seizure free on CBZ as their first antiepileptic drug with a seizure frequency of at least two seizures per month during the retrospective baseline period of 3 months. Criteria for exclusion were not satisfying the inclusion criteria; inability to give informed consent (e.g. language barrier); absence and/or myoclonic seizures; acute or progressive neurological disorders; alcohol or other substance abuse; psychiatric disease; and mental retardation. The parents of patients younger than 18 years of age were asked for informed consent. The protocol of the study was approved by the ethics committee of the First Hospital of Shanxi Medical University.
Procedure
Neurologists of two hospitals of the Shanxi Medical University identified eligible patients. After enrolment, patients were randomized to either VPA add-on or PRM add-on. The dose of the add-on drugs were titrated in three steps with weekly intervals. The dose of VPA and PRM were escalated in a stepwise fashion (200 mg/day, 400 mg/day and 600 mg/day for VPA; 250 mg/day, 500 mg/day, 750 mg/day for PRM). The doses were not increased further when patients were seizure free or experienced adverse effects. After the titration period (of flexible length), the dosages were held stable during a 3-month maintenance period. The procedures followed were in accordance with the ethical standards of the medical ethical committees of the hospitals involved and with the Helsinki Declaration of 1975.
The following outcome measures were used: seizure frequency (for which patients were given diaries) and adverse effects. Serum levels were collected at the first control visit and when doses were changed. Serum level samples were taken before ingestion of the morning dose after patients had used a stable dose for 1-2 weeks. Samples were analyzed by the laboratory of the Shanxi Medical University with high-pressure liquid chromatography. The observed serum level of three drugs are in therapeutic level (4-10 mg/L for CBZ, 50-100 mg/L for VPA, and 20-40 mg/L for phenobarbital, the main metabolite of PRM).
Statistics
Sample size calculation was based on the proportion of patients seizure free. With 61 patients in each treatment group, the study had a power of 80% and a significance level of 0.05 to show a difference of 25% in patients becoming seizure free. The number of patients completing maintenance phase, reaching seizure freedom or a significant seizure reduction were compared using risk difference and using relative risks with 95% confidence intervals. Seizure frequencies were compared with the baseline seizure frequencies and CBZ serum levels were compared with the baseline serum levels using nonparametric tests (Wilcoxon signed-rank).
Results
Patients
One hundred and thirty-six (136) patients were enrolled in the study, and all of these patients were randomized. Sixty-eight patients were randomized to receive add-on valproate, and 68 to receive add-on primidone. The characteristics of the patients in the two groups are shown in Table 1 .
Effectiveness
In the add-on valproate group, 63 of 68 patients completed the maintenance period, whereas 57 patients completed the maintenance period in the PRM group (Fig. 1) . This difference almost reached statistical significance (chi square test: P = 0.07). The most common reason for withdrawal in both groups was adverse events (Fig. 1). 
Efficacy
In both treatment groups, seizure frequencies were reduced significantly from CBZ monotherapy for all seizure types (Table 2) . When comparing the effects of the add-on drugs on an ''intention to treat'' basis, there was a trend favouring the VPA group in ''risk'' of becoming seizure free and significantly more patients in the VPA group experienced a greater than 50% seizure reduction compared to the PRM group (Table 3) . Similar results are obtained by a ''per protocol'' analysis.
Adverse effects
One patient withdrew from the VPA group due to dizziness and three due to gastrointestinal complaints (nausea). In the PRM group, three patients withdrew from the trial due to dizziness, three patients due to drowsiness and one patient due to gastrointestinal complaints. This treatment difference did not reach statistical significance (risk difference 6% and relative risk 0.43 with 95% confidence interval 0.12-1.59). Adverse effects in other patients were mild and disappeared while patients continued to use the drugs.
Dosages/serum levels
The average dosages used in this study were 583 mg/day for VPA and 596 mg/day for PRM (Table 4 ). The maximal dosages used in maintenance period were 1500 mg/day for PRM and 1600 mg/ day for VPA. The plasma concentrations of CBZ in monotherapy were significantly higher than the CBZ levels in the two treatment groups (Table 4 ).
Discussion
Our results indicate a trend towards better efficacy in the addon valproate group, compared to the add-on primidone group in carbamazepine-unresponsive patients with partial epilepsy. In our study, 51.4% patients experienced a >50% seizure reduction in the CBZ-VPA group. Similar efficacy data were reported for this combination by other groups. Dean and Penry found that 54 of 100 carbamazepine-unresponsive patients with partial epilepsy had a greater than 50% seizure reduction upon addition of valproate. 5 Fifteen patients became seizure free. Walker and Koon performed a study in which patients with complex partial seizures first all received VPA monotherapy. 6 Patients who did not respond sufficiently to this were given CBZ monotherapy and when they again insufficiently responded they were given the combination of VPA and CBZ. Of the 17 patients not responding to either CBZ or VPA monotherapy, 12 benefited from their combination, with 6 becoming seizure free. There has only been one report about the effectiveness of the combination of primidone and carbamazepine in epilepsy patients. 7 This was a report on a group of 31 patients who failed to respond to monotherapy with CBZ at the maximum tolerated dose. The patients were allocated to add-on treatment with VPA (15 patients) or PRM (16 patients). The results were better for the latter group: 10 patients experienced a greater than 50% seizure reduction, whereas this was the case for only 4 of the patients in the CBZ/VPA group. Tolerability did not differ between the two groups. We found that CBZ serum levels were lower in combination therapy than in monotherapy. Similarly, Rambeck found that the mean serum concentration of CBZ is lower when the drug is given in combination with primidone and valproate than when CBZ is given alone, whereas the mean concentration of CBZ-epoxide is increased especially by valproate. 8 Our results indicated no significant differences were found concerning tolerability. In the animal experiments performed by Bourgeois and co-workers, the efficacy of the CBZ/VPA and CBZ/ PRM combinations were additive. 9 The toxicity of the CBZ/PRM combination was found to be additive, while infra-additive toxicity was found for the CBZ/VPA combination. Infra-additive toxicity may allow for higher dosages to be used, resulting in better effectiveness. 10 When we look at mechanisms of action of the respective drugs, it is unclear why one of these combinations should perform better than the other, as VPA and PRM seem to mediate their effects through similar actions, i.e. through actions on the GABAergic system and blockade of sodium channels. There may be some criticism of the design of our study. First of all, PRM was chosen of phenobarbital despite the fact that primidone may be associated with more adverse effects during the first months of treatment.
11 However, the percentage of patients failing on PRM due to adverse effects was limited in our study, and the efficacy of PRM and phenobarbital may be expected to be similar. Secondly, the average dosages used for the add-on treatment were in the low range of dosages used in clinical practice. It is possible that more patients would have experienced a greater than 50% seizure reduction and more patients would have become seizure free, when VPA and PRM would have been titrated to higher dosages. However, it is likely that more patients would have withdrawn from the study due to adverse effects, when higher dosages had been used. The reason for the careful titration schedule was the hypothesis that low dosages of two treatments perform better than high dosages of a single drug. 12 It should also be pointed out that the effect of a drug, whether in monotherapy or in combination therapy, is already apparent at low dosages in most patients. 13 A third point of criticism may be the relatively short maintenance period of 3 months used in our study. Shorvon has stated that a drug should be assessed at a therapeutic dose during a period three to five times the previous interval between seizures. 14 In placebocontrolled add-on trials, patients with at least four seizures per month are enrolled and this type of study usually has a 8-12 week maintenance period. 15 With the relatively high baseline seizure frequencies in our study, we feel that the length of the maintenance period is justifiable. The results of this trial suggest that for patients unresponsive to carbamazepine, adding valproate is preferable to adding primidone. Because of restricted health care resources, one may be justified to try phenobarbital before trying valproate. Valproate is still considerably less expensive than the new antiepileptic drugs. Percentages of patients in different outcome groups are given (with number of patients in parentheses); superscript letter (a): significant difference between treatment groups; 95% CI: 95% confidence interval. 
